$599

Bayer Q4 ’22 Earnings Update

Bayer hosted its Q4 ’22 earnings call (press release; slides) and provided updates across its business, including Kerendia (finerenone) in the context of the ongoing US launch and LCM initiatives. Below, FENIX provides highlights and insights from the call.

This content is for Read Less members only.
Register
Already a member? Log in here